Lifeward Ltd. (LFWD)
NASDAQ: LFWD · Real-Time Price · USD
0.7095
+0.0020 (0.28%)
Dec 12, 2025, 9:40 AM EST - Market open
Lifeward Revenue
Lifeward had revenue of $5.72M in the quarter ending June 30, 2025, a decrease of -14.66%. In the year 2024, Lifeward had annual revenue of $25.66M with 85.24% growth.
Revenue (ttm)
$25.66M
Revenue Growth
+85.24%
P/S Ratio
0.34
Revenue / Employee
$306,225
Employees
80
Market Cap
12.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.66M | 11.81M | 85.24% |
| Dec 31, 2023 | 13.85M | 8.34M | 151.39% |
| Dec 31, 2022 | 5.51M | -455.00K | -7.63% |
| Dec 31, 2021 | 5.97M | 1.57M | 35.81% |
| Dec 31, 2020 | 4.39M | -480.00K | -9.85% |
| Dec 31, 2019 | 4.87M | -1.67M | -25.55% |
| Dec 31, 2018 | 6.55M | -1.21M | -15.58% |
| Dec 31, 2017 | 7.75M | 1.88M | 32.10% |
| Dec 31, 2016 | 5.87M | 2.12M | 56.67% |
| Dec 31, 2015 | 3.75M | -205.00K | -5.19% |
| Dec 31, 2014 | 3.95M | 2.36M | 148.80% |
| Dec 31, 2013 | 1.59M | 616.00K | 63.37% |
| Dec 31, 2012 | 972.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LFWD News
- 9 days ago - Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval - GlobeNewsWire
- 25 days ago - UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton - GlobeNewsWire
- 27 days ago - Lifeward Ltd. (LFWD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Lifeward Ltd. Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Lifeward to Report Third Quarter Financial Results on November 14, 2025 - GlobeNewsWire
- 3 months ago - First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton - GlobeNewsWire
- 3 months ago - Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton - GlobeNewsWire
- 4 months ago - Lifeward Ltd. (LFWD) Q2 2025 Earnings Call Transcript - Seeking Alpha